• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

起始年龄和筛查频率对预防高危地区食管鳞状细胞癌的经济评估。

Age at Initiation and Frequency of Screening to Prevent Esophageal Squamous Cell Carcinoma in High-risk Regions: an Economic Evaluation.

机构信息

Medical Decision and Economic Group, Department of Pharmacy, Ren Ji Hospital, South Campus, School of Medicine, Shanghai Jiaotong University, Shanghai, China.

Department of Gastroenterology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China.

出版信息

Cancer Prev Res (Phila). 2020 Jun;13(6):543-550. doi: 10.1158/1940-6207.CAPR-19-0477. Epub 2020 Mar 9.

DOI:10.1158/1940-6207.CAPR-19-0477
PMID:32152149
Abstract

The aim of this study was to identify the economic screening strategies for esophageal squamous cell carcinoma (ESCC) in high-risk regions. We used a validated ESCC health policy model for comparing different screening strategies for ESCC. Strategies varied in terms of age at initiation and frequency of screening. Model inputs were derived from parameter calibration and published literature. We estimated the effects of each strategy on the incidence of ESCC, costs, quality-adjusted life-year (QALY), and incremental cost-effectiveness ratios (ICERs). Compared with no screening, all competing screening strategies decreased the incidence of ESCC from 0.35% to 72.8%, and augmented the number of QALYs (0.002-0.086 QALYs per person) over a lifetime horizon. The screening strategies initiating at 40 years of age and repeated every 1-3 years, which gained over 70% of probabilities that was preferred in probabilistic sensitivity analysis at a $1,151/QALY willingness-to-pay threshold. Results were sensitive to the parameters related to the risks of developing basal cell hyperplasia/mild dysplasia. Endoscopy screening initiating at 40 years of age and repeated every 1-3 years could substantially reduce the disease burden and is cost-effective for the general population in high-risk regions.

摘要

本研究旨在确定高危地区食管鳞状细胞癌(ESCC)的经济筛查策略。我们使用经过验证的 ESCC 卫生政策模型来比较 ESCC 的不同筛查策略。策略在起始年龄和筛查频率方面有所不同。模型输入来自参数校准和已发表的文献。我们估计了每种策略对 ESCC 发病率、成本、质量调整生命年(QALY)和增量成本效益比(ICER)的影响。与不筛查相比,所有竞争的筛查策略均将 ESCC 的发病率从 0.35%降至 72.8%,并在终生范围内增加了 QALY(每人 0.002-0.086 QALY)的数量。起始年龄为 40 岁且每 1-3 年重复一次的筛查策略,在 1151 美元/QALY 的支付意愿阈值下,在概率敏感性分析中获得了超过 70%的偏好概率。结果对与发展基底细胞增生/轻度发育不良风险相关的参数敏感。起始年龄为 40 岁且每 1-3 年重复一次的内镜筛查可以显著降低疾病负担,并且对于高危地区的一般人群来说具有成本效益。

相似文献

1
Age at Initiation and Frequency of Screening to Prevent Esophageal Squamous Cell Carcinoma in High-risk Regions: an Economic Evaluation.起始年龄和筛查频率对预防高危地区食管鳞状细胞癌的经济评估。
Cancer Prev Res (Phila). 2020 Jun;13(6):543-550. doi: 10.1158/1940-6207.CAPR-19-0477. Epub 2020 Mar 9.
2
High-resolution microendoscopy for esophageal cancer screening in China: A cost-effectiveness analysis.中国食管癌筛查的高分辨率显微内镜检查:成本效益分析
World J Gastroenterol. 2015 May 14;21(18):5513-23. doi: 10.3748/wjg.v21.i18.5513.
3
Estimated Cost-effectiveness of Endoscopic Screening for Upper Gastrointestinal Tract Cancer in High-Risk Areas in China.中国高危地区上消化道癌内镜筛查的成本效益估计
JAMA Netw Open. 2021 Aug 2;4(8):e2121403. doi: 10.1001/jamanetworkopen.2021.21403.
4
Endoscopy for upper GI cancer screening in the general population: a cost-utility analysis.普通人群上消化道癌筛查的内镜检查:成本效用分析。
Gastrointest Endosc. 2011 Sep;74(3):610-624.e2. doi: 10.1016/j.gie.2011.05.001. Epub 2011 Jul 13.
5
Development of an Empirically Calibrated Model of Esophageal Squamous Cell Carcinoma in High-Risk Regions.在高危地区建立食管鳞癌经验校准模型的研究。
Biomed Res Int. 2019 May 22;2019:2741598. doi: 10.1155/2019/2741598. eCollection 2019.
6
Selection of high-risk individuals for esophageal cancer screening: A prediction model of esophageal squamous cell carcinoma based on a multicenter screening cohort in rural China.高危人群食管癌筛查的选择:基于中国农村多中心筛查队列的食管鳞癌预测模型。
Int J Cancer. 2021 Jan 15;148(2):329-339. doi: 10.1002/ijc.33208. Epub 2020 Aug 6.
7
A Model To Identify Individuals at High Risk for Esophageal Squamous Cell Carcinoma and Precancerous Lesions in Regions of High Prevalence in China.中国高发地区食管鳞癌及癌前病变高危人群识别模型。
Clin Gastroenterol Hepatol. 2017 Oct;15(10):1538-1546.e7. doi: 10.1016/j.cgh.2017.03.019. Epub 2017 Mar 23.
8
Improved esophageal squamous cell carcinoma screening effectiveness by risk-stratified endoscopic screening: evidence from high-risk areas in China.基于风险分层的内镜筛查提高食管鳞癌筛查效果:来自中国高危地区的证据。
Cancer Commun (Lond). 2021 Aug;41(8):715-725. doi: 10.1002/cac2.12186. Epub 2021 Jun 19.
9
Performance of Prediction Models for Esophageal Squamous Cell Carcinoma in General Population: A Systematic Review and External Validation Study.一般人群中食管鳞状细胞癌预测模型的性能:一项系统评价和外部验证研究。
Am J Gastroenterol. 2024 May 1;119(5):814-822. doi: 10.14309/ajg.0000000000002629. Epub 2023 Dec 13.
10
Cost-effectiveness analysis of neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced esophageal squamous cell carcinoma based on the NEOCRTEC5010 trial.基于 NEOCRTEC5010 试验的新辅助放化疗联合手术与单纯手术治疗局部晚期食管鳞癌的成本效果分析。
Radiother Oncol. 2019 Dec;141:27-32. doi: 10.1016/j.radonc.2019.07.031. Epub 2019 Aug 17.

引用本文的文献

1
The expression and biological role of complement C1s in esophageal squamous cell carcinoma.补体C1s在食管鳞状细胞癌中的表达及生物学作用
Open Life Sci. 2024 Jul 24;19(1):20220915. doi: 10.1515/biol-2022-0915. eCollection 2024.
2
Long-term esophageal cancer risk and distinct surveillance intervals after a single endoscopy screening: a multicentre population-based cohort study.单次内镜筛查后的长期食管癌风险及不同监测间隔:一项基于多中心人群的队列研究。
EClinicalMedicine. 2023 Aug 30;63:102201. doi: 10.1016/j.eclinm.2023.102201. eCollection 2023 Sep.
3
Optimal starting age of endoscopic screening for esophageal cancer in China: A multicenter prospective cohort study.
中国食管癌内镜筛查的最佳起始年龄:一项多中心前瞻性队列研究。
Cancer Med. 2023 Apr;12(8):9988-9998. doi: 10.1002/cam4.5727. Epub 2023 Apr 7.
4
Cost-Effectiveness Analysis of Toripalimab Plus Paclitaxel and Cisplatin as First-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma.特瑞普利单抗联合紫杉醇和顺铂一线治疗晚期或转移性食管鳞癌的成本-效果分析。
Adv Ther. 2023 Mar;40(3):1019-1030. doi: 10.1007/s12325-022-02402-z. Epub 2023 Jan 9.
5
Cost-effectiveness of precision screening for esophageal cancer based on individualized risk stratification in China: Real-world evidence from the ESECC trial.基于个体风险分层的中国食管癌精准筛查的成本效益:来自ESECC试验的真实世界证据
Front Oncol. 2022 Nov 30;12:1002693. doi: 10.3389/fonc.2022.1002693. eCollection 2022.
6
Cost-Effectiveness Analysis of Camrelizumab Placebo Added to Chemotherapy as First-Line Therapy for Advanced or Metastatic Esophageal Squamous Cell Carcinoma in China.卡瑞利珠单抗联合安慰剂加化疗作为中国晚期或转移性食管鳞状细胞癌一线治疗的成本效益分析
Front Oncol. 2021 Dec 1;11:790373. doi: 10.3389/fonc.2021.790373. eCollection 2021.